PCP cautions public vs unregistered diabetes drugsThe Philippine College of Physicians (PCP) raised its concern on the increasing promotion, sale and use of compounded GLP-1 receptor agonists, including the compounded versions of semaglutide and tirzepatide used in treating type 2 diabetes and obesity. MANILA, Philippines — A group of health experts warned the public against the use of drugs being marketed for the treatment of type 2 diabetes and obesity but are compounded and unregistered with the Food and Drug Administration. The Philippine College of Physicians (PCP) raised its concern on the increasing promotion, sale and use of compounded GLP-1 receptor agonists, including the compounded versions of semaglutide and tirzepatide used in treating type 2 diabetes and obesity. The group noted that international regulatory agencies and pharmacovigilance reports have identified serious dangers associated with compounded GLP-1 receptor agonists that have not undergone proper regulatory review. “Unlike approved medicines, these compounded products have not undergone rigorous clinical trials, manufacturing oversight or regulatory evaluation required by the Food and Drug Administration,” the PCP said.

Source: Philippine Star March 14, 2026 16:57 UTC